In this study, the NSCLC patients with PAK7 mutations showed a better prognosis than those without PAK7 mutations in an ICI-treated cohort, independent of the common driver gene mutations, while in the patients, who did not receive immunotherapy, the PAK7 mutations did not clinically benefit the patients. Here, PAK5 is linked to non-small cell lung carcinoma.